1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025

Welcome to New Orleans

Long-Acting Anti-Infectives: Where Do We Stand?

Pharmacological Considerations of Routes of Administration for Long-Acting Injectable Products

Regulatory Considerations for Long-Acting Anti-Infectives: Challenges and Opportunities

Current and Future Perspectives in HIV Prevention: Approved Drugs and Therapies in Development

Long-Acting Antiretroviral Monoclonal Antibodies: Revolutionizing HIV Prevention

Getting It Right This Time: The Impact of PEPFAR Stop Work Orders on Injectable PrEP and Implications for LEN Rollout

#1 Proof-of-Concept Study of Oral VH4004280, a New HIV-1 Capsid Inhibitor

Abstract

Implementation Challenges in LMICs

Laboratory Considerations in the Age of Long-Acting Agents: A Focus on HIV Resistance

#101 LB-#1 What Do Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine Think About It?

Abstract

#2 Utilization and Effectiveness of Cabotegravir + Rilpivirine in People with HIV (PWH) with Viremia at Treatment Initiation

Abstract

#3 Novel Ultra-Long-Acting Injectable Formulations of Bictegravir

Abstract

Pharmacokinetic Considerations of Long-Acting Anti-Infective Administration During Pregnancy

The Long-Acting Anti-Infective Agents for Children and Adolescents: Are We Nearly There Yet?

#4 Facilitators and barriers to long-acting injectable antiretroviral therapy uptake among youth living with HIV in Cape Town, South Africa: A COM-B analysis

Abstract

#5 Cabotegravir and Rilpivirine in Pregnancy: A Multi-Center Study Evaluating HIV viral suppression, Perinatal and Neonatal Outcomes

Abstract

#102 LB-#2 Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2)

Abstract

#10 Black Transgender and Cisgender Women’s Experiences With PrEP and Reasons for Choosing Injectable PrEP

Abstract

#11 PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP

Abstract

#12 Feasibility of Delivering Long-Acting Antiretroviral Injectables to Key Populations in Uganda: Lessons from HIV Prevention Programs

Abstract

#13 Long-Acting PrEP Awareness and Interest among Black and Hispanic Men in the US

Abstract

#14 Evaluation of Patient Experience and Treatment Tolerability in the Phase 2b Study of VH3810109 (N6LS) and Cabotegravir Long-Acting Injections for HIV Treatment

Abstract

#15 Higher real-world adherence and persistence with long-acting cabotegravir plus rilpivirine (CAB+RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV (PWH) in the US: the ABOVE study

Abstract

#16 Similar Virologic Outcomes and Isolated Viremic Event (Blips, Low-Level Viremia, Suspected Virologic Failure) Frequency Between Oral and Long-Acting Antiretroviral Therapy: Pooled Analysis of Phase 3/3b Cabotegravir + Rilpivirine Long-Acting Studies

Abstract

#17 Patient Preferences for Long Acting Injectable and Oral ART: A Discrete Choice Experiment in the US

Abstract

#18 Clinical Outcomes at Month 12 After Initiation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND)

Abstract

#19 Comparison of treatment-emergent resistance associated mutations among single tablet regimens and cabotegravir+rilpivirine for the treatment of virologically suppressed people with HIV: A Systematic Literature Review and Network Meta-Analysis

Abstract

#20 High and comparable efficacy between CAB+RPV LA and oral ART across a range cardiovascular risk profiles and statin use: A post hoc analysis of CAB+RPV LA Phase 3/3b studies

Abstract

#21 Evaluation of the interest of Cameroonian adolescents living with HIV/AIDS to long-acting antiretroviral treatment: the CIPHER-ADOLA Study

Abstract

#22 Patient Experiences at Month 6 After Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US

Abstract

#23 Comparative analysis of screening and preventative measures and healthcare resource utilization among people with HIV receiving long-acting cabotegravir plus rilpivirine or oral antiretroviral therapy in the US: the ABOVE study

Abstract

#24 Feasibility, Fidelity, and Effectiveness of Administering CABENUVA in Infusion Centers

Abstract

#26 Impact of introduction of Long-Acting Injectable Antiretroviral on Viral Suppression Among People with HIV and Adherence Challenges in a Low-Barrier, Support-Intensive Program

Abstract

#27 Cost-Effectiveness of Cabotegravir Long-Acting for HIV Pre-Exposure Prophylaxis (PrEP): A Systematic Review of Modelling Studies

Abstract

#28 Maintained Virologic Suppression with Cabotegravir-Rilpivirine in PLWH on Dialysis

Abstract

#29 How Do Injection Site Reactions Influence Preferences for Long-Acting Injectable HIV Treatment?

Abstract

#30 Expanding the use of long-acting HIV treatment: will hepatitis B have a field day?

Abstract